Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Ventyx Biosciences, Inc. (NASDAQ: VTYX) securities.
If you suffered a loss on your Ventyx investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: Oct 21 2021 - Nov 06 2023
CASE DETAILS: The filed complaint alleges that Ventyx Biosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) VTX958, the Company's lead clinical product candidate, was less effective in treating psoriasis than defendants had led investors to believe; (ii) as a result, VTX958’s clinical and/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx’s business prospects following the initial public offering were thus inflated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





